|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||208.53 - 210.50|
|52 Week Range||200.47 - 276.69|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||21.22|
|Earnings Date||Nov 02, 2021|
|Forward Dividend & Yield||7.04 (3.36%)|
|Ex-Dividend Date||Aug 16, 2021|
|1y Target Est||247.45|
Subscribe to Yahoo Finance Plus to view Fair Value for AMGNLearn more
Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will be paid on December 8, 2021, to all stockholders of record as of the close of business on November 16, 2021.
AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit Amgen Inc (NASDAQ: AMGN) with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity. AstraZeneca's AZD5991 belongs to the same class therapy. The trial suspension, noted on ClinicalTrials.gov, came on October 19: "The study has been put on hold to allow further evaluation of safety-related information,"
Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Amgen Inc. (NASDAQ: AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla for the treatment of adults with mild to moderate plaque psoriasis. The company also said the FDA had set a Prescription Drug